Open-label Safety Study of Dipraglurant (ADX48621) in Patients With Parkinson's Disease Receiving Levodopa-based Therapy
Status:
Recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
This open-label study is designed to assess the long-term safety and tolerability of
dipraglurant in PD patients for up to 52 weeks (1 week at 150 mg per day and 11 weeks at 300
mg per day) for patients that have completed an Addex sponsored double-blind clinical trial
of dipraglurant.